Also trades as: 0M40.L (LSE) · $vol 0M
ZYNE NASDAQ
Zynerba Pharmaceuticals, Inc.
1W: +1.6%
1M: -3.7%
3M: +271.4%
1Y: +90.9%
3Y: -64.0%
5Y: -81.4%
$1.30
Last traded 2023-10-13 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$35M
+4.1% ▲
Net Income
-$35M
+7.4% ▲
EPS (Diluted)
$-0.82
+14.6% ▲
EBITDA
-$35M
+4.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $86K | $0 | $0 | $0 | $0 |
| YoY Growth | +1086.2% | -100.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $86K | $0 | $0 | $0 | $0 |
| Gross Margin | 100.0% | — | — | — | — |
| R&D Expenses | $27M | $20M | $36M | $21M | $21M |
| SG&A Expenses | $13M | $14M | $16M | $15M | $14M |
| Operating Expenses | $40M | $34M | $52M | $37M | $35M |
| Operating Income | -$40M | -$34M | -$52M | -$37M | -$35M |
| Operating Margin | -46974.2% | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | -$216K |
| Income Before Tax | -$40M | -$33M | -$51M | -$37M | -$35M |
| Tax Expense | $0 | -$2M | -$933K | $291K | -$216K |
| Net Income | -$40M | -$31M | -$50M | -$38M | -$35M |
| Net Margin | -46408.3% | — | — | — | — |
| EPS (Diluted) | $-2.61 | $-1.43 | $-1.87 | $-0.96 | $-0.82 |
| EBITDA | -$40M | -$34M | -$52M | -$36M | -$35M |
| Shares Outstanding | 15M | 22M | 27M | 39M | 43M |